Apogee Therapeutics, Inc.
NASDAQApogee Therapeutics heads into the week with a freshly cut analyst rating colliding against a short position that has grown 18% in a month — the tension between a broadly bullish Street and a determined bear camp is the defining feature of this setup. The most immediate catalyst is a downgrade filed this morning. Canaccord Genuity's Edward Nash cut APGE from Buy to Hold, even while…
Snapshot as of 12 Jul 2026
Apogee Therapeutics heads into the week with a freshly cut analyst rating colliding against a short position that has grown 18% in a month — the tension between a broadly bullish Street and a determined bear camp is…
Apogee Therapeutics reports today against a backdrop of distinctly defensive positioning — options markets are flashing the clearest caution signal seen in months, even as short sellers hold a structurally large stake…
Apogee Therapeutics enters its June 9 Q1 readout with the Street tilting constructive and short sellers trimming positions for the third consecutive month — an unusual alignment for a pre-revenue biotech trading at 16%…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for APGE — free to start on ORTEX.
Sign up for free →Open APGE on ORTEX